Vaccinia virus vaccination is expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus
S. F. Ahmed, M. S. Sohail, A. A. Quadeer, M. R. McKay
The paper assesses cross-reactivity of vaccinia virus vaccines against new monkeypox virus variants, finding that immune responses remain highly cross-reactive.
bioRxiv · Jun 23, 2022 · PreprintImmunology